公开(公告)号：US12129236B2

公开(公告)日：2024-10-29

申请号：US17204206

申请日：2021-03-17

申请人： CANCER RESEARCH TECHNOLOGY LIMITED

发明人： Alison E. McGonagle ,  Allan M. Jordan ,  Bohdan Waszkowycz ,  Colin P. Hutton ,  Ian D. Waddell ,  James R. Hitchin ,  Kate M. Smith ,  Niall M. Hamilton

IPC分类号： C07D235/26 ,  A61P35/00 ,  C07D307/85 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04 ,  C07D413/04 ,  C07D413/06 ,  C07D413/14 ,  C07D417/04 ,  C07D417/06 ,  C07D417/14

CPC分类号： C07D235/26 ,  A61P35/00 ,  C07D307/85 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04 ,  C07D413/04 ,  C07D413/06 ,  C07D413/14 ,  C07D417/04 ,  C07D417/06 ,  C07D417/14

摘要： The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

公开(公告)号：US10995073B2

公开(公告)日：2021-05-04

申请号：US16662997

申请日：2019-10-24

申请人： CANCER RESEARCH TECHNOLOGY LIMITED

发明人： Alison E. McGonagle ,  Allan M. Jordan ,  Bodhan Waszkowycz ,  Colin P. Hutton ,  Ian D. Waddell ,  James R. Hitchin ,  Kate M. Smith ,  Niall M. Hamilton

IPC分类号： C07D235/26 ,  C07D403/04 ,  C07D413/04 ,  A61K31/4184 ,  C07D413/14 ,  C07D401/06 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04 ,  C07D413/06 ,  C07D417/04 ,  C07D417/14 ,  C07D417/06 ,  A61P35/00 ,  C07D307/85

摘要： The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

公开(公告)号：US10508086B2

公开(公告)日：2019-12-17

申请号：US15533819

申请日：2015-12-17

申请人： CANCER RESEARCH TECHNOLOGY LIMITED

发明人： Alison E. McGonagle ,  Allan M. Jordan ,  Bohdan Waszkowycz ,  Colin P. Hutton ,  Ian D. Waddell ,  James R. Hitchin ,  Kate M. Smith ,  Niall M. Hamilton

IPC分类号： C07D231/56 ,  A61K31/416 ,  C07D235/26 ,  C07D413/14 ,  C07D401/06 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04 ,  C07D413/04 ,  C07D413/06 ,  C07D417/04 ,  C07D417/06 ,  C07D417/14 ,  A61P35/00 ,  C07D307/85 ,  C07D403/04

摘要： The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

公开(公告)号：US10239843B2

公开(公告)日：2019-03-26

申请号：US15533804

申请日：2015-12-11

申请人： CANCER RESEARCH TECHNOLOGY LIMITED

发明人： Alison E. McGonagle ,  Allan Jordan ,  Bohdan Waszkowycz ,  Colin Hutton ,  Ian Waddell ,  James R. Hitchin ,  Kate Mary Smith ,  Niall M. Hamilton

IPC分类号： A61K31/517 ,  C07D239/96 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D215/227 ,  C07D217/22 ,  C07D217/24 ,  C07D401/06 ,  C07D403/06 ,  C07D403/14 ,  C07D405/06 ,  C07D409/14 ,  C07D239/88 ,  C07D239/90 ,  C07D239/91 ,  C07D413/06 ,  C07D417/06 ,  C07D241/44 ,  C07D417/14 ,  C07D237/32 ,  C07D471/04

摘要： The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.